CN112957350A - A herba Houttuyniae aerosol inhalation solution and its preparation method - Google Patents
A herba Houttuyniae aerosol inhalation solution and its preparation method Download PDFInfo
- Publication number
- CN112957350A CN112957350A CN202110140294.8A CN202110140294A CN112957350A CN 112957350 A CN112957350 A CN 112957350A CN 202110140294 A CN202110140294 A CN 202110140294A CN 112957350 A CN112957350 A CN 112957350A
- Authority
- CN
- China
- Prior art keywords
- solution
- injection
- houttuynia cordata
- preparation
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 239000000443 aerosol Substances 0.000 title description 14
- 229940041682 inhalant solution Drugs 0.000 title description 9
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 title description 3
- 239000000243 solution Substances 0.000 claims abstract description 113
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 42
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 42
- 238000002347 injection Methods 0.000 claims abstract description 24
- 239000007924 injection Substances 0.000 claims abstract description 24
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- BUCIWTBCUUHRHZ-UHFFFAOYSA-K potassium;disodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O BUCIWTBCUUHRHZ-UHFFFAOYSA-K 0.000 claims description 2
- IGHGOYDCVRUTSU-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O IGHGOYDCVRUTSU-UHFFFAOYSA-M 0.000 claims description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 claims description 2
- 238000002663 nebulization Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000000889 atomisation Methods 0.000 abstract description 8
- 239000007853 buffer solution Substances 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- 239000008215 water for injection Substances 0.000 description 44
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 11
- 238000011049 filling Methods 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 238000007789 sealing Methods 0.000 description 11
- 238000005303 weighing Methods 0.000 description 11
- -1 compound disodium hydrogen phosphate Chemical class 0.000 description 9
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 238000002664 inhalation therapy Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 241000758769 Houttuynia Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a houttuynia cordata solution preparation for atomization and inhalation, belonging to the field of pharmaceutics. A solution preparation for atomizing and inhaling houttuynia cordata comprises (1) effective components of houttuynia cordata; (2) isotonic agent and solvent, and buffer solution. The solution preparation prepared by the invention makes up the blank of the current domestic market, is specially designed for patients for atomization and inhalation, is matched with an atomizer for use, is convenient to use, has different administration routes compared with houttuynia cordata injection, reduces the dosage and improves the safety.
Description
Technical Field
The invention relates to a houttuynia cordata solution preparation for atomization and inhalation and a preparation method thereof, belonging to the field of pharmaceutics.
Background
The houttuynia cordata injection has the effects of clearing heat, detoxifying and promoting diuresis, and is mainly suitable for lung abscess, phlegm heat cough, leucorrhea, urinary tract infection, carbuncle furuncle and the like. However, in recent years, with the increase of the population for clinical medication, the adverse reaction reports are increasing, so that the research and development of novel medicaments with definite curative effect and rapid effect have important practical significance.
Disclosure of Invention
The invention mainly solves the technical problem of providing a safe, effective and excellent-quality houttuynia cordata atomizing inhalation solution preparation; the invention also provides a preparation method of the preparation.
The invention is realized by the following technical scheme:
a solution formulation for the aerosol inhalation of houttuynia cordata comprising:
(1) effective component of herba Houttuyniae;
(2) isotonic agents and solvents;
buffers may also be added.
Wherein the mass ratio of the effective component of the houttuynia cordata to the isotonic agent is 1:1-1: 5.
The active ingredients are prepared by the following steps:
steam distilling 2000g of fresh houttuynia cordata, collecting 200ml of primary distillate, redistilling, collecting 1000ml of secondary distillate, and properly concentrating to obtain the effective component of the invention.
The isotonic agent is one of sodium chloride, potassium chloride, magnesium chloride, calcium chloride, glucose, xylitol, and sorbitol.
The buffer solution is one of citric acid-sodium citrate, citric acid-disodium hydrogen phosphate, potassium dihydrogen phosphate-disodium hydrogen phosphate, citric acid-sodium hydroxide, and citric acid-disodium hydrogen phosphate.
The pH of the aerosolized inhalation solution is from 3.0 to 8.5; preferably the pH is 4.0-7.0.
The dosage of the atomized inhalation solution is 0.1-0.8 times of the dosage of the houttuynia cordata injection; the preferable dosage is 0.3-0.6 times of the dosage of the houttuynia cordata injection.
The houttuynia cordata solution preparation for atomization and inhalation can be used for treating lung abscess, phlegm heat cough and the like.
The invention has the advantages that the invention provides a new formulation which is superior to the houttuynia cordata injection, the formulation is directly inhaled from the respiratory tract, is locally aggregated into higher concentration, directly acts on a receptor or a target receptor on the surface of the airway to play a role, and can be directly absorbed from the mucosa of the airway and the lung, the administration mode can directly deliver the effective components to the focus, and the invention has the advantages of safety, effectiveness, high bioavailability, low dose and quick and effective treatment, thereby having obvious advantages.
The solution preparation prepared by the invention makes up for the blank of the current domestic market, can avoid the potential safety hazard caused by the lack of special preparation medicines for inhalation therapy and the use of houttuynia cordata injection for replacing the inhalation therapy. The solution preparation prepared by the invention is specially designed for patients for atomization and inhalation, is matched with an atomizer for use, is convenient and fast in use process, has different administration routes compared with houttuynia cordata injection, reduces the dosage and improves the safety.
The beneficial effects of the present invention are further illustrated by the following test examples:
preparing 60 phlegm-heat cough rat models, randomly dividing the models into a normal control group, a positive control group, a drug group I, a drug group II, a drug group III and a drug group IV, wherein each group comprises 10 rats, and the normal control group is administered with the same amount of normal saline for intravenous injection; the positive control group is given with the houttuynia cordata injection for intravenous injection; the first, second, third and fourth drug groups are respectively administered with the houttuynia cordata atomized inhalation solution (the dosage is respectively 0.1 time, 0.3 time, 0.6 time and 0.8 time of the houttuynia cordata injection), and are continuously administered for 5 days, and the cure rate, the adverse reaction incidence rate and the drug peak concentration in lung tissues and blood after the last administration of the drug are observed. In particular, see the following table:
table conditions after treatment of each group
Therefore, each drug group has a better treatment effect on the phlegm-heat cough rats, wherein the treatment effects of the drug groups II, III and IV are obviously better than those of the positive control group, and no adverse reaction occurs.
In conclusion, the medicine group has small dosage and less adverse reaction, the medicine is mainly gathered in the lung to form higher concentration, the medicine effect components can directly act on the focus, the bioavailability is high, and the low-dosage quick and effective treatment is realized, so the medicine has obvious advantages.
Similarly, the effect of the medicine group on treating other indications is also obviously better than that of the houttuynia injection.
The houttuynia cordata atomization inhalation solution has the treatment effect obviously superior to that of houttuynia cordata injection, fills up the blank of the special houttuynia cordata atomization inhalation solution in the domestic market at present, greatly reduces the dosage compared with the houttuynia cordata injection, is 0.1-0.8 times, preferably 0.3-0.6 times of the houttuynia cordata injection, changes the administration route and reduces the occurrence of adverse reactions, and therefore, the houttuynia cordata atomization inhalation solution has creative and prominent substantive characteristics and remarkable progress.
Detailed Description
The preparation process and the materials used in the preparation or the dosage of the materials used in the preparation in the following pharmaceutical preparation examples are not limited to the words, and all the preparation methods containing the pharmaceutical composition provided by the present invention are within the protection scope of the present invention.
Example 1
(1) Preparation of active ingredients:
steam distilling 2000g of fresh houttuynia cordata, collecting 200ml of primary distillate, redistilling, collecting 1000ml of secondary distillate, and properly concentrating to obtain the effective component of the invention.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding appropriate amount of water for injection into sodium chloride and citric acid, and stirring to dissolve to obtain solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.4mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 4.5-6.5, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Example 2
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; taking sodium chloride, adding a proper amount of water for injection, and stirring to dissolve to obtain a solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.4mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 4.0-6.0, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Example 3
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding a proper amount of water for injection into magnesium chloride and citric acid, and stirring to dissolve to obtain a solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.2mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 5.0-6.0, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Example 4
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding appropriate amount of water for injection into calcium chloride and citric acid, and stirring to dissolve to obtain solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.4mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 5.0-7.0, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Example 5
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding appropriate amount of water for injection into sodium chloride and citric acid, and stirring to dissolve to obtain solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and adding an appropriate amount of sodium citrate and an appropriate amount of water for injection to prepare a solution of 0.2mol/L, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 3.0-5.0, adding an appropriate amount of water for injection, filling and sealing to obtain the product.
Example 6
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding appropriate amount of water for injection into glucose and citric acid, and stirring to dissolve to obtain solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.4mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 4.5-5.5, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Example 7
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding appropriate amount of water for injection into xylitol and citric acid, and stirring to dissolve to obtain solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and adding an appropriate amount of sodium hydroxide and an appropriate amount of water for injection to prepare a solution of 0.1mol/L, slowly adding into the solution 3 while stirring, adjusting the pH value to 6.5-8.5, adding an appropriate amount of water for injection, filling and sealing to obtain the product.
Example 8
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; taking sodium chloride and potassium dihydrogen phosphate, adding a proper amount of water for injection, and stirring to dissolve to obtain a solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.4mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 5.5-7.5, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Example 9
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding appropriate amount of water for injection into sorbitol and citric acid, and stirring to dissolve to obtain solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.2mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 6.0-8.0, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Example 10
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding appropriate amount of water for injection into sodium chloride and citric acid, and stirring to dissolve to obtain solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.4mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 7.5-8.5, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Example 11
(1) Preparation of active ingredients: the same as in example 1.
(2) Preparation of a solution for houttuynia cordata aerosol inhalation:
weighing the effective components according to the prescription amount, adding a proper amount of water for injection, and uniformly stirring to obtain a solution 1; adding a proper amount of water for injection into magnesium chloride, and stirring to dissolve the magnesium chloride to obtain a solution 2; mixing the solution 1 and the solution 2, and uniformly stirring to obtain a solution 3; and preparing a solution of 0.2mol/L by adding a proper amount of disodium hydrogen phosphate and a proper amount of water for injection, slowly adding the solution into the solution 3 while stirring, adjusting the pH value to 6.0-7.0, adding a proper amount of water for injection, filling and sealing to obtain the compound disodium hydrogen phosphate injection.
Claims (9)
1. A solution preparation for atomizing and inhaling houttuynia cordata is characterized by comprising (1) effective components of houttuynia cordata; (2) isotonic agents and solvents;
wherein the mass ratio of the effective components to the isotonic agent is 1:1-1: 5.
2. The formulation according to claim 1, wherein the active ingredient is prepared by:
steam distilling 2000g of fresh houttuynia cordata, collecting 200ml of primary distillate, redistilling, collecting 1000ml of secondary distillate, and properly concentrating to obtain the effective component of the invention.
3. The formulation of claim 1, wherein the isotonicity agent is one of sodium chloride, potassium chloride, magnesium chloride, calcium chloride, glucose, xylitol, and sorbitol.
4. The formulation of claim 1, further comprising a buffer.
5. The formulation of claim 4, wherein the buffer is one of citric acid-sodium citrate, citric acid-disodium hydrogen phosphate, potassium dihydrogen phosphate-disodium hydrogen phosphate, citric acid-sodium hydroxide, and citric acid-disodium hydrogen phosphate.
6. The formulation of claim 1, wherein the pH of the solution for nebulization and inhalation is from 3.0 to 8.5.
7. The formulation of claim 6, wherein the pH of the solution for nebulization and inhalation is from 4.0 to 7.0.
8. The formulation of claim 1, wherein the amount of the solution for inhalation is 0.1 to 0.8 times the amount of the injection solution of houttuynia cordata.
9. The formulation of claim 8, wherein the amount of the solution for inhalation is 0.3 to 0.6 times the amount of the injection solution of houttuynia cordata.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110140294.8A CN112957350A (en) | 2016-03-01 | 2016-03-01 | A herba Houttuyniae aerosol inhalation solution and its preparation method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110140294.8A CN112957350A (en) | 2016-03-01 | 2016-03-01 | A herba Houttuyniae aerosol inhalation solution and its preparation method |
CN201610112778.0A CN107137502A (en) | 2016-03-01 | 2016-03-01 | A kind of cordate houttuynia Neulized inhalation pharmaceutical solutions and preparation method thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610112778.0A Division CN107137502A (en) | 2016-03-01 | 2016-03-01 | A kind of cordate houttuynia Neulized inhalation pharmaceutical solutions and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112957350A true CN112957350A (en) | 2021-06-15 |
Family
ID=59783058
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610112778.0A Pending CN107137502A (en) | 2016-03-01 | 2016-03-01 | A kind of cordate houttuynia Neulized inhalation pharmaceutical solutions and preparation method thereof |
CN202110140294.8A Pending CN112957350A (en) | 2016-03-01 | 2016-03-01 | A herba Houttuyniae aerosol inhalation solution and its preparation method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610112778.0A Pending CN107137502A (en) | 2016-03-01 | 2016-03-01 | A kind of cordate houttuynia Neulized inhalation pharmaceutical solutions and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN107137502A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109745441A (en) * | 2017-11-03 | 2019-05-14 | 北京盈科瑞创新药物研究有限公司 | One seed ginseng wheat stops Neulized inhalation pharmaceutical solutions and preparation method thereof of coughing |
CN110314187A (en) * | 2018-03-29 | 2019-10-11 | 北京盈科瑞创新药物研究有限公司 | A kind of sucking silver-colored a kind of reed mentioned in ancient books pharmaceutical solutions and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1626169A (en) * | 2003-12-11 | 2005-06-15 | 华中科技大学同济医学院附属同济医院 | Houttuynia cordata nasal preparation and its production process |
CN102462771A (en) * | 2010-11-18 | 2012-05-23 | 裘建社 | Preparation method of traditional Chinese medicine houttuynia cordata injection |
-
2016
- 2016-03-01 CN CN201610112778.0A patent/CN107137502A/en active Pending
- 2016-03-01 CN CN202110140294.8A patent/CN112957350A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1626169A (en) * | 2003-12-11 | 2005-06-15 | 华中科技大学同济医学院附属同济医院 | Houttuynia cordata nasal preparation and its production process |
CN102462771A (en) * | 2010-11-18 | 2012-05-23 | 裘建社 | Preparation method of traditional Chinese medicine houttuynia cordata injection |
Non-Patent Citations (6)
Title |
---|
刘国卿: "《医学常用试剂配制手册》", vol. 1, 30 June 1998, 重庆大学出版社, pages: 30 - 31 * |
刘琰等: "《烧伤感染》", vol. 1, 30 September 2014, 湖北科学技术出版社, pages: 212 * |
孙国珍等: "鱼腥草注射液雾化吸入治疗呼吸道感染107例疗效观察", 《中成药》, vol. 23, no. 6, 30 June 2001 (2001-06-30), pages 421 - 423 * |
杨光彩 等: "《生物化学实验指导》", vol. 1, 31 August 2001, 华南理工大学出版社, pages: 163 - 165 * |
罗明生等: "《药剂辅料大全》", vol. 2, 31 January 2006, 四川科学技术出版社, pages: 74 * |
颜正华: "《中药注射剂不良反应与安全应用》", vol. 1, 31 May 2012, 中国中医药出版社, pages: 102 * |
Also Published As
Publication number | Publication date |
---|---|
CN107137502A (en) | 2017-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0418232A (en) | sulfoalkyl ether cyclodextrin and corticosteroid inhalant formulation from a unit dose suspension | |
JPH0669957B2 (en) | Glutathione aerosol formulation | |
CN106974898B (en) | Solution preparation for acute bronchitis aerosol inhalation and preparation method thereof | |
EP3932400B1 (en) | Peramivir solution type inhalant and preparation method therefor | |
JP2021506897A (en) | Solution formulation for aerosol inhalation of hoodstain and its manufacturing method | |
CN107126432A (en) | Lian Bizhi Neulized inhalation pharmaceutical solutionses and preparation method thereof | |
CN112957350A (en) | A herba Houttuyniae aerosol inhalation solution and its preparation method | |
CN113368208A (en) | Antiviral aerosol inhalation solution preparation and preparation method thereof | |
CN114344380A (en) | Asthma-relieving aerosol inhalation solution preparation and preparation method thereof | |
CN106667974A (en) | Preparation method of terbutaline sulfate solution for inhalation | |
CN101569684B (en) | Inhalation aerosol of plant extract for treating asthma and preparation method | |
CN114848707B (en) | Oral cavity atomized liquid and its use | |
CN107334754B (en) | Qingkailing solution preparation for aerosol inhalation and preparation method thereof | |
CN112999204A (en) | Shuanghuanglian aerosol inhalation solution preparation and preparation method thereof | |
CN109745301A (en) | A kind of carbocisteine Neulized inhalation pharmaceutical solutions and preparation method thereof | |
CN117205186B (en) | Leifenacin inhalation spray and preparation method thereof | |
CN113318099A (en) | Inhalable ambroxol hydrochloride composition and application thereof | |
CN102166213A (en) | Composition using levalbuterol and ipratropium bromide as active ingredients | |
CN114099480A (en) | Atomizing inhalation type polydatin solution and preparation method thereof | |
CN101023953A (en) | Composition for treating bronchia asthma | |
CN107137483A (en) | One kind, which is breathed heavily, can control Neulized inhalation pharmaceutical solutions and preparation method thereof | |
CN115137713B (en) | Amphotericin B aerosol inhalation preparation and preparation method thereof | |
CN106806360A (en) | A kind of Sodium New Houttuyfonate Neulized inhalation pharmaceutical solutions and preparation method thereof | |
CN114159414A (en) | Favipiravir solution for atomization inhalation and preparation method thereof | |
CN113209169A (en) | Ginseng and aconite root aerosol inhalation solution preparation and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210615 |
|
RJ01 | Rejection of invention patent application after publication |